Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
Go back to Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting| (NASDAQ: CMPX) | Delayed: 2.10 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.10 | 52 Week High | $ | |||
| Open | $2.10 | 52 Week Low | $ | |||
| Day High | $2.10 | P/E | N/A | |||
| Day Low | $2.10 | EPS | $ | |||
| Volume | 32,223 | |||||
